Acetylcysteine prevents apoptotic DNA fragmentation and maintains long-term survival in the absence of other trophic support in serum-deprived PC12 cells. Acetylcysteine also prevents death of PC12 cells and sympathetic neurons^[2].
Acetylcysteine causes dose-dependent reductions in viability in rat and human aortic smooth muscle cells^[3].
Acetylcysteine activates the Ras-extracellular signal-regulated kinase (ERK) pathway in PC12 cells. Acetylcysteine protects neuronal cells from death evoked by withdrawal of trophic support. Acetylcysteine increases nitric oxide (NO) release from protein-bound stores in vascular tissue. Acetylcysteine pretreatment of PC12 cells interferes with NGF-dependent signaling and neurite outgrowth, and it is suggested that Acetylcysteine interferes with redox-sensitive steps in the NGF mechanism^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Acetylcysteine (150, 300 mg/kg) treatment significantly reduces liver transaminases in all groups of treatment, mostly in group Acetylcysteine 300. Lung glutathione peroxidase is significantly increases in group Acetylcysteine 300 (P=0.04), while the other oxidation biomarkers show no significant differences^[6].
Acetylcysteine improves cognition of 12-month-old SAMP8 mice in both the T-maze footshock avoidance paradigm and the lever press appetitive task without inducing non-specific effects on motor activity, motivation to avoid shock, or body weight^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

NCT NumberSponsorConditionStart DatePhaseNCT00247507Far Eastern Memorial HospitalAnemia|Atherosclerosis|End-Stage Renal Disease|Oxidative Stress|Pro-InflammationSeptember 2005Phase 4NCT03493178Baylor College of Medicine|The Methodist Hospital Research InstituteMild Cognitive ImpairmentApril 14, 2018Early Phase 1NCT02249546National Taiwan University HospitalHelicobacter Pylori InfectionSeptember 2014Phase 4

163.19

Solid

C₅H₉NO₃S

616-91-1

乙酰半胱氨酸

• Ketones, Aldehydes, Acids

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

In Vitro: 

H₂O : 163 mg/mL (998.84 mM; ultrasonic and adjust pH to 7 with NaOH)

DMSO : ≥ 100 mg/mL (612.78 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量1 mg5 mg10 mg1 mM6.1278 mL30.6391 mL61.2783 mL5 mM1.2256 mL6.1278 mL12.2557 mL10 mM0.6128 mL3.0639 mL6.1278 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶